Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Semin Arthritis Rheum. 2022 Oct 26;58:152110. doi: 10.1016/j.semarthrit.2022.152110

Figure 2. Concepts, Areas and Domains for Outcome Measures in ICI-Inflammatory Arthritis and ICI-PMR.

Figure 2.

Âdverse events (harms) are a mandatory domain within OMERACT; (n) = number of studies with included outcome

*Other related manifestations: tenosynovitis, dactylitis, spondyloarthritis, remitting symmetrical seronegative synovitis with pitting edema

Legend: ANA = anti-nuclear antibody, RF = rheumatoid factor, CCP = anti-cyclic citrullinated peptide, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, HLA = human leukocyte antigen, irAE = immune-related adverse event, OS = overall survival, PFS= progression free survival, IA = inflammatory arthritis, ICI = immune checkpoint inhibitor.